SKYA vs ACU vs BAX Stock Comparison

SkyAI, Acme United and Baxter International Prices as of Nov 5, 2026 Peers: Industry group
1 more company in this comparison (RVP) Create a free account to keep reading and compare up to 10 companies.
SKYA SkyAI, Inc.
$2.92 +55.3% 1M -30.6% 1Y
Market cap
$212.68M
P/E
–
Revenue (TTM)
$174.18K
Div. yield
–
Medical Supplies Healthcare
2 wins
ACU Acme United Corp
$69.02 +9.4% 1M +81.4% 1Y
Market cap
$262.15M
P/E
26.7x
Revenue (TTM)
$211.60M
Div. yield
–
Medical Supplies Healthcare
7 wins
BAX Baxter International Inc
$25.63 +5.3% 1M +42.8% 1Y
Market cap
$13.23B
P/E
–
Revenue (TTM)
$11.61B
Div. yield
0.01%
Medical Supplies Healthcare
1 win

Head to Head

10 decided of 12

Acme United leads on 7 of the 12 questions below (Acme United 7, SkyAI 2, Baxter International 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionSKYAACUBAXLeader
Larger companyMarket capitalisation $212.68M $262.15M $13.23B BAX
Cheaper on earningsLower P/E, profitable companies only -0.5x 26.7x -18.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 0.0x 25.2x 12.6x SKYA
Faster revenue growthRevenue growth, trailing twelve months +108.0% +9.0% +5.3% SKYA
More profitableNet margin, trailing twelve months -228,220.7% 4.6% -6.2% ACU
Better return on capitalReturn on invested capital — 7.3% -1.4% ACU
Less leveragedLower net debt / EBITDA — 1.1x 9.0x ACU
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.01% –
Better 1-year returnPrice return, last 12 months -30.6% +81.4% +42.8% ACU
Better 5-year returnAnnualised price return, 5 years — +14.0%/yr -20.0%/yr ACU
Less volatileAnnualised volatility, 1 year 104.7% 30.9% 42.9% ACU
Higher overall scoreMean of the five percentile scores vs peers 27/100 71/100 43/100 ACU

Percentile Scorecard

SKYAACUBAX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisSKYAACUBAX
Valuation 4 #221 of 229 95 #13 of 229 86 #32 of 229
Growth 4 #213 of 221 57 #96 of 221 14 #191 of 221
Profitability 1 #209 of 210 81 #41 of 210 64 #77 of 210
Financial Health 95 #13 of 240 57 #104 of 240 17 #199 of 240
Shareholder Returns 33 #99 of 147 65 #52 of 147 34 #98 of 147
Overall 27 71 43
  • SKYA ranked among 247 companies in Medical Devices and Diagnostics
  • ACU ranked among 247 companies in Medical Devices and Diagnostics
  • BAX ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodSKYAACUBAXSPY
1 month +55.3%+9.4%+5.3% -5.9%
3 months +149.6%+23.2%-5.1% -4.6%
6 months +56.1%+65.0%+46.5% +0.2%
Year to date +43.8%+71.2%+34.1% +7.5%
1 year -30.6%+81.4%+42.8% +8.2%
3 years -99.9%+107.6%-25.7% +68.3%
3 years, per year -90.0%+27.6%-9.4% +19.0%
5 years —+92.8%-67.2% +56.5%
5 years, per year —+14.0%-20.0% +9.4%
10 years —+222.5%-45.5% +251.5%
10 years, per year —+12.4%-5.9% +13.4%

Risk

MeasureSKYAACUBAXSPY
Volatility, 1Y 104.7%30.9%42.9% 13.6%
Downside volatility, 1Y 104.1%24.8%44.3% 14.2%
Beta vs S&P 500, 1Y 2.150.281.05 1.00
Return / volatility, 1Y -0.292.641.00 0.60
Max drawdown, 5Y -100.0%-41.7%-82.3% -25.4%
From 52-week high -30.6%-2.7%-9.6% -5.9%
52-week high $4.21$70.92$28.35 $779.14
52-week low $0.95$35.50$15.80 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleSKYAACUBAX
P/E now vs peer median -0.5xmedian 26.9x 26.9xmedian 26.9x -18.3xmedian 26.9x
P/S now vs peer median 1,209xmedian 2.9x 1.3xmedian 2.9x 1.1xmedian 2.9x
EV/EBITDA now vs peer median -0.5xmedian 17.5x 11.8xmedian 17.5x 27.1xmedian 17.5x
P/FCF now vs peer median -1.0xmedian 26.4x 17.1xmedian 26.4x 11.4xmedian 26.4x
P/B now vs peer median 1.3xmedian 2.3x 2.2xmedian 2.3x 2.0xmedian 2.3x
PEG now vs peer median 0.01median 0.88 0.90median 0.88 0.58median 0.88

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsSKYAACUBAX
Revenue $174.18K $211.60M $11.61B
Gross profit $324.68K $84.82M $3.49B
Operating income -$374.36M $14.48M -$221.00M
Net income -$397.51M $9.82M -$723.00M
Free cash flow -$201.93M $15.48M $1.16B
R&D $475.55K – $519.00M
EPS (diluted) $-5.51 $2.37 $-1.39
Cash & equivalents $12.07M $5.04M $1.98B
Total debt – $32.33M $8.60B
Shares (diluted) 72.09M 4.14M 520.00M
Enterprise value $167.38M $244.17M $5.11B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricSKYAACUBAX
P/E -0.5x 26.9x -18.3x
P/FCF -1.0x 17.1x 11.4x
P/Operating cash flow -14.6x 10.1x 8.0x
P/S 1,209x 1.3x 1.1x
P/B 1.3x 2.2x 2.0x
P/Tangible book 16.2x 3.0x 5.1x
EV/EBITDA -0.5x 11.8x 27.1x
EV/EBIT -0.5x 20.2x -90.0x
EV/Revenue 1,139x 1.4x 1.7x
EV/FCF -1.0x 18.9x 17.1x
EV/Operating cash flow -13.8x 11.2x 11.9x
PEG (3Y EPS CAGR) 0.01 0.90 0.58

Growth

14 metrics
MetricSKYAACUBAX
Revenue growth (1Y) 108.0% 9.0% 5.3%
Revenue CAGR (3Y) 19.4% 3.1% 0.7%
Gross profit growth (1Y) – 11.0% -7.1%
Gross profit CAGR (3Y) – 8.5% -7.7%
Operating income growth (1Y) -8,055% 3.3% -136.3%
Operating income CAGR (3Y) -240.7% 20.1% 4.2%
Net income growth (1Y) -54,854% -5.1% -112.0%
Net income CAGR (3Y) -268.2% 36.0% -31.6%
EPS growth (1Y) -658.6% -5.9% -109.6%
EPS CAGR (3Y) -100.6% 29.7% -31.5%
Operating cash flow growth (1Y) -356.8% 43.2% 97.4%
Operating cash flow CAGR (3Y) -24.4% 12.0% 0.6%
Free cash flow growth (1Y) -6,031% 26.7% 243.5%
Free cash flow CAGR (3Y) -196.9% 1.5% -5.0%

Profitability

14 metrics
MetricSKYAACUBAX
Gross margin 186.4% 40.1% 30.1%
EBITDA margin -214,892% 11.7% 6.3%
Operating margin -214,931% 6.8% -1.9%
Pretax margin -221,236% 5.9% -1.6%
Net margin -228,221% 4.6% -6.2%
FCF margin -115,934% 7.3% 10.0%
Operating cash flow margin -8,259% 12.3% 14.3%
Return on equity -280.7% 8.2% -11.4%
Return on assets -276.3% 5.0% -3.7%
Return on invested capital – 7.3% -1.4%
Return on capital employed -223.1% 8.9% -1.4%
Asset turnover 0.0x 1.1x 0.6x
Cash conversion (OCF / net income) 0.0x 2.7x -2.3x
Stock comp / revenue 52,451% 0.9% 0.9%

Financial Health

11 metrics
MetricSKYAACUBAX
Debt / assets – 16.1% 44.3%
Debt / equity – 0.3x 1.3x
Net debt / EBITDA – 1.1x 9.0x
Debt / FCF – 2.1x 7.4x
Liabilities / assets 1.9% 39.5% 66.5%
Equity / assets 98.1% 60.5% 33.5%
Interest coverage – – –
Current ratio 5.3x 3.2x 1.8x
Quick ratio 4.4x 1.3x 1.0x
Cash ratio 4.2x 0.1x 0.5x
Altman Z-score 29.80 4.50 2.38

Shareholder Returns

7 metrics
MetricSKYAACUBAX
Dividend yield – 0.9% 0.2%
Net buyback yield -0.6% -0.2% -0.2%
Shareholder yield -0.6% 0.7% 0.0%
Payout ratio (earnings) – – -14.1%
Payout ratio (FCF) – – 8.8%
Dividend growth (1Y) – – -75.0%
Dividend CAGR (3Y) – – -44.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusSKYAACUBAX
Forward P/E 0.0xFY2026 25.2xFY2026 12.6xFY2026
EPS, next fiscal year $2,362.06FY2026 $2.74FY2026 $2.03FY2026
EPS growth, next FY – +10.0%FY2026 -8.1%FY2026
EPS growth, the year after – +20.4% -5.9%
Revenue, next fiscal year $70.01MFY2026 $217.94MFY2026 $11.14BFY2026
Revenue growth, next FY +34,200.1%FY2026 +10.9%FY2026 -0.9%FY2026
Revenue growth, the year after +17.5% +0.4% +11.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersSKYAACUBAX
Held by institutions – 73.5% 100.0%
Institutions holding – 84 692
Change in shares held, QoQ – +1.3% +5.2%
Institutions buying – 47 358
Institutions selling – 21 194
Buyers to sellers – 2.24 1.85

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

SKYAACUBAX
SKYA 1.00 -0.02 0.08
ACU -0.02 1.00 0.19
BAX 0.08 0.19 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, SKYA, ACU and BAX?

Baxter International (BAX) is the largest by market capitalisation: SkyAI (SKYA) $212.68M, Acme United (ACU) $262.15M, Baxter International (BAX) $13.23B.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: SkyAI (SKYA) +108.0%, Acme United (ACU) +9.0%, Baxter International (BAX) +5.3%.

Which company is more profitable?

Acme United (ACU) has the highest net margin (SkyAI (SKYA) -228,220.7%, Acme United (ACU) 4.6%, Baxter International (BAX) -6.2%). On return on invested capital, Acme United (ACU) leads (Acme United (ACU) 7.3%, Baxter International (BAX) -1.4%).

Which stock has performed better?

Over the past year Acme United (ACU) returned the most: SkyAI (SKYA) -30.6%, Acme United (ACU) +81.4%, Baxter International (BAX) +42.8%. Over five years, Acme United (ACU) compounded fastest (Acme United (ACU) +14.0%/yr, Baxter International (BAX) -20.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: SkyAI (SKYA) 0.00%, Acme United (ACU) 0.00%, Baxter International (BAX) 0.01%. SkyAI (SKYA) and Acme United (ACU) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Acme United (ACU) has been the steadiest (SkyAI (SKYA) 104.7%, Acme United (ACU) 30.9%, Baxter International (BAX) 42.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, SKYA, ACU and BAX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Acme United (ACU) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.